Brief: FDA Approves First Mesenchymal Stromal Cell Therapy To Treat Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast

18/12/2024 23:13

Dec 18 (Reuters) - 
  
    * FDA: APPROVES FIRST MESENCHYMAL STROMAL CELL THERAPY TO
TREAT
STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
    * FDA: GRANTED APPROVAL OF RYONCIL TO MESOBLAST, INC.
    * FDA: APPROVED RYONCIL TREATMENT OF STEROID-REFRACTORY
ACUTE
GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS 2 MONTHS OF AGE
& OLDER

Source text:  ID: 

 ((Reuters.Briefs@thomsonreuters.com;))